These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 22266571)

  • 1. Erythropoietic stimulating agents and quality of a patient's life: individualizing anemia treatment.
    Kliger AS; Fishbane S; Finkelstein FO
    Clin J Am Soc Nephrol; 2012 Feb; 7(2):354-7. PubMed ID: 22266571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Individualizing decision-making--resurrecting the doctor-patient relationship in the anemia debate.
    Agarwal R
    Clin J Am Soc Nephrol; 2010 Jul; 5(7):1340-6. PubMed ID: 20448071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Regarding the optimal hemoglobin target range in renal anemia].
    Maurin N
    Med Klin (Munich); 2008 Sep; 103(9):633-7. PubMed ID: 18813886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are there implications from the Trial to Reduce Cardiovascular Events with Aranesp Therapy study for anemia management in dialysis patients?
    Berns JS
    Curr Opin Nephrol Hypertens; 2010 Nov; 19(6):567-72. PubMed ID: 20601876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An economic evaluation of erythropoiesis-stimulating agents in CKD.
    Clement FM; Klarenbach S; Tonelli M; Wiebe N; Hemmelgarn B; Manns BJ
    Am J Kidney Dis; 2010 Dec; 56(6):1050-61. PubMed ID: 20932621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transfusion burden among patients with chronic kidney disease and anemia.
    Lawler EV; Bradbury BD; Fonda JR; Gaziano JM; Gagnon DR
    Clin J Am Soc Nephrol; 2010 Apr; 5(4):667-72. PubMed ID: 20299366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Anemia: guidelines comparison].
    Del Vecchio L
    G Ital Nefrol; 2009; 26(6):686-94. PubMed ID: 19918751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health-related quality of life and hemoglobin levels in chronic kidney disease patients.
    Finkelstein FO; Story K; Firanek C; Mendelssohn D; Barre P; Takano T; Soroka S; Mujais S
    Clin J Am Soc Nephrol; 2009 Jan; 4(1):33-8. PubMed ID: 18987300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The FDA's perspective on the risk for rapid rise in hemoglobin in treating CKD anemia: Quo Vadis.
    Singh AK
    Clin J Am Soc Nephrol; 2010 Apr; 5(4):553-6. PubMed ID: 20203166
    [No Abstract]   [Full Text] [Related]  

  • 11. An expert opinion on the current treatment of anemia in patients with kidney disease.
    Locatelli F; Del Vecchio L
    Expert Opin Pharmacother; 2012 Mar; 13(4):495-503. PubMed ID: 22296648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survey of attitude of physicians on updates in the management of anemia in chronic kidney disease patients.
    Souqiyyeh MZ; Shaheen FA
    Saudi J Kidney Dis Transpl; 2009 May; 20(3):410-6. PubMed ID: 19414943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maintaining control over haemoglobin levels: optimizing the management of anaemia in chronic kidney disease.
    Bárány P; Müller HJ
    Nephrol Dial Transplant; 2007 Jun; 22 Suppl 4():iv10-iv18. PubMed ID: 17526545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. It's time to compare anemia management strategies in hemodialysis.
    Coyne DW
    Clin J Am Soc Nephrol; 2010 Apr; 5(4):740-2. PubMed ID: 20299363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triumph and tragedy: anemia management in chronic kidney disease.
    Novak JE; Szczech LA
    Curr Opin Nephrol Hypertens; 2008 Nov; 17(6):580-8. PubMed ID: 18941350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease.
    Palmer SC; Navaneethan SD; Craig JC; Johnson DW; Tonelli M; Garg AX; Pellegrini F; Ravani P; Jardine M; Perkovic V; Graziano G; McGee R; Nicolucci A; Tognoni G; Strippoli GF
    Ann Intern Med; 2010 Jul; 153(1):23-33. PubMed ID: 20439566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
    Voravud N; Sriuranpong V; Suwanrusme H
    J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initiation of anaemia management in patients with chronic kidney disease not on dialysis in the Veterans Health Administration.
    Lawler EV; Gagnon DR; Fink J; Seliger S; Fonda J; Do TP; Gaziano JM; Bradbury BD
    Nephrol Dial Transplant; 2010 Jul; 25(7):2237-44. PubMed ID: 20083469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between hemoglobin level and quality of life in anemic patients with chronic kidney disease receiving epoetin alfa.
    Lefebvre P; Vekeman F; Sarokhan B; Enny C; Provenzano R; Cremieux PY
    Curr Med Res Opin; 2006 Oct; 22(10):1929-37. PubMed ID: 17022852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents.
    Aapro MS; Link H
    Oncologist; 2008; 13 Suppl 3():33-6. PubMed ID: 18458123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.